Fig. 5. Combined treatment with Menin inhibitor and venetoclax induces synergistic in vitro lethality in patient-derived AML cells expressing MLL1-r or mtNPM1 with or without FLT3 alterations.

A–F Patient-derived AML cells with MLL1 rearrangement or mtNPM1 with or without FLT3 alterations were treated with the indicated concentrations of SNDX-50469 and/or venetoclax for 48–72 h. The % non-viable cells were determined by staining with TO-PRO-3 iodide and flow cytometry analysis. Delta synergy scores were determined by the ZIP method. Synergy scores > 1.0 indicate a synergistic interaction of the two agents in the combination.